

## Appendix: Project Details

ID: G2025-125

<b>Project Title</b>	Development and performance evaluation of Iso-PAS technology for mpox detection (Iso-PAS Mpox)
<b>Collaboration Partners</b>	1. NIPRO CORPORATION (Japan) 2. TBA Co., Ltd. (Japan) 3. Japan Institute for Health Security (JIHS/ Japan) 4. PATH (USA) 5. Institut National de Recherche Biomédicale (INRB/ Democratic Republic of the Congo)
<b>Disease</b>	Mpox
<b>Intervention</b>	Diagnostic
<b>Stage</b>	Technical Feasibility
<b>Awarded Amount</b>	JPY 71,279,693 (USD 462,555)
<b>Status</b>	New Project
<b>Summary</b>	<p>[Project objective] A test kit will be developed that can distinguish between MPXV Clade I and Clade II using the Iso-PAS method, an inexpensive and simple genetic testing method. A future aim is to register the test kit on the WHO Emergency Use Listing (EUL) following the accumulation of proven data from MPXV outbreak regions.</p> <p>[Project design] The following activities are to be implemented in the project: 1) Development of a prototype Iso-PAS Mpox test kit, and its performance evaluation. 2) Performance study of the prototype kit using clinical specimens from the DRC.</p>
<b>Project Detail</b>	<a href="https://www.ghitfund.org/investment/portfoliodetail/detail/250/en">https://www.ghitfund.org/investment/portfoliodetail/detail/250/en</a>

\*All amounts are listed at an exchange rate of USD1 = JPY154.10, the approximate exchange rate on October 31, 2025.

To learn more about the GHIT Fund's investments, please visit

Investment Overview: <https://www.ghitfund.org/investment/overview/en>

Portfolio: <https://www.ghitfund.org/investment/portfolio/en>

Advancing Portfolio: <https://www.ghitfund.org/investment/advancingportfolio/en>

Clinical Candidates: <https://www.ghitfund.org/investment/clinicalcandidates/en>